Abbott Vascular

Spotlight

		Learn more about Abbott Vascular's flagship drug eluting stent, the XIENCE V Everolimus Eluting Coronary Stent System.

		CMO Newsletter A message from Chuck Simonton, MD, Chief Medical Officer, Abbott Vascular.

		Abbott's Bioabsorbable Stent Featured in Popular Science A recent Popular Science article highlights the innovation of Abbott's fully bioabsorbable coronary device.

Investors & Media

Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME Drug Eluting Stent, Advancing Leadership Position
Abbott Initiates Trial of Next-Generation XIENCE V™ Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
Abbott Announces Launch of Next-Generation Embolic Protection System
Abbott’s XIENCE V Demonstrates Impressive Low Rates of Repeat Procedures, Stent Thrombosis and Major Adverse Cardiac Events in Complex, “Real World” Patients in SPIRIT V Study
Abbott Introduces Two New Products for the Treatment of Peripheral Artery Disease
Abbott Initiates U.S. Study of Absolute Pro Peripheral Stent System for Iliac Artery Disease

AP2928724 Rev. B

Home | Site Map | Contact Us | Privacy Policy | Terms of Use

Copyright © 2006-2009 Abbott Laboratories. Abbott Park, Illinois, U.S.A.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.